VIDEO: Ixo-vec for neovascular AMD shows treatment burden reduction at 26 weeks
Click Here to Manage Email Alerts
In this Healio Video Perspective from the Retina Society meeting, Mark R. Barakat, MD, discusses the 26-week interim analysis for Ixo-vec for the treatment of neovascular age-related macular degeneration.
In the phase 2 LUNA study, Ixo-vec (ixoberogene soroparvovec, Adverum Biotechnologies) gene therapy showed positive results in reducing treatment burden in previously treated patients at two doses.
According to Barakat, the therapy was “well tolerated across both doses. We now know that the local steroid prophylaxis seems to be working well — certainly better than just the oral prednisone or the intravitreal dexamethasone by itself.”
Collapse
Barakat M, et al. Ixoberogene soroparvovec (Ixo-vec) IVT gene therapy for neovascular AMD: 26-week interim analysis results from the phase 2 LUNA study. Presented at: Retina Society meeting; Sept. 11-15, 2024; Lisbon, Portugal.
Read more about
Click Here to Manage Email Alerts